Exosomes as promising frontier approaches in future cancer therapy

Table 1 The clinical trials of cargoes for cancer therapy

Study title	Conditions	Interventions	NCT number	Study status	Sponsor
Study investigating the ability of plant exosomes to deliver curcumin to normal and colon cancer tissue	Colon cancer	Dietary supplement: Curcumin conjugated with plant exosomes	NCT01294072	Recruiting	University of Louisville
Inhibitory exosomes in treating participants with metastatic pancreas cancer with KRASG12D mutation	KRAS NP004976.2: p.G12D; Metastatic Pancreatic Adenocarcinoma; Pancreatic ductal adenocarcinoma; Stage IV pancreatic cancer	Drug: Mesenchymal stromal cells-derived exosomes with KRASG12D siRNA	NCT03608631	Active; Not Recruiting	M.D. Anderson Cancer Center
A study of exoASO-STAT6 (CDK-004) in patients with advanced hepatocellular carcinoma and patients with liver metastases from either primary gastric cancer or colorectal cancer	Advanced hepatocellular carcinoma; Gastric cancer metastatic to liver; Colorectal cancer metastatic to liver	Drug: CDK-004	NCT05375604	Terminated	Codiak BioSciences
Trial of a vaccination with tumor antigen-loaded dendritic cell-derived exosomes	Non small cell lung cancer	Biological: DEX2	NCT01159288	Completed	Gustave Roussy, Cancer Campus, Grand Paris

Data collected from ClinicalTrials.gov accessed on August 20, 2024. exoASO-STAT6: Exosomes with antisense oligonucleotide-signal transducer and activator of transcription 6; CDK-004: Codiak BioSciences product-004; DEX: Dendritic cell-derived exosomes; NCT: National clinical trial.